We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is CareDx (CDNA - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CareDx is a member of the Medical sector. This group includes 1025 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CareDx is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for CDNA's full-year earnings has moved 16.7% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, CDNA has moved about 113.7% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 2.1% on a year-to-date basis. This means that CareDx is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Clover Health Investments, Corp. (CLOV - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 260.3%.
For Clover Health Investments, Corp. the consensus EPS estimate for the current year has increased 7.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, CareDx is a member of the Medical Services industry, which includes 59 individual companies and currently sits at #138 in the Zacks Industry Rank. On average, stocks in this group have lost 5.4% this year, meaning that CDNA is performing better in terms of year-to-date returns.
In contrast, Clover Health Investments, Corp. falls under the Medical Info Systems industry. Currently, this industry has 42 stocks and is ranked #34. Since the beginning of the year, the industry has moved -3.7%.
Investors interested in the Medical sector may want to keep a close eye on CareDx and Clover Health Investments, Corp. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is CareDx (CDNA - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CareDx is a member of the Medical sector. This group includes 1025 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CareDx is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for CDNA's full-year earnings has moved 16.7% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, CDNA has moved about 113.7% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 2.1% on a year-to-date basis. This means that CareDx is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Clover Health Investments, Corp. (CLOV - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 260.3%.
For Clover Health Investments, Corp. the consensus EPS estimate for the current year has increased 7.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, CareDx is a member of the Medical Services industry, which includes 59 individual companies and currently sits at #138 in the Zacks Industry Rank. On average, stocks in this group have lost 5.4% this year, meaning that CDNA is performing better in terms of year-to-date returns.
In contrast, Clover Health Investments, Corp. falls under the Medical Info Systems industry. Currently, this industry has 42 stocks and is ranked #34. Since the beginning of the year, the industry has moved -3.7%.
Investors interested in the Medical sector may want to keep a close eye on CareDx and Clover Health Investments, Corp. as they attempt to continue their solid performance.